Recent progress of METTL3 inhibitors for cancer therapeutics: design, optimization and potential applications
Yun Zhang1, Mengxiang Quan1, Qinlan Chen2
1Affiliated Yongkang First People's Hospital and School of Pharmacy, Hangzhou Medical College Hangzhou 310013 China wzuny@hmc.edu.cn.
Abstract:
Acute myeloid leukaemia (AML) is a clonal proliferative malignant hematologic disease of hematopoietic stem cells, characterized by the accumulation of immature progenitor cells and the inhibition of hematopoietic function due to blocked differentiation, which is a genetically heterogeneous and dynamic disease and the most common type of leukemia in adults. Studies have shown that methyltransferase-like protein 3 (METTL3) is highly expressed in AML cells, regulating methylation modifications that drive the development of leukemia. This discovery has become a major breakthrough in the treatment of AML, as it is possible to address common issues in current chemotherapy, such as drug resistance, by developing METTL3 inhibitors. This review summarizes the strategies for discovering and optimizing the medicinal chemistry of METTL3 inhibitors, provides a reference for future drug development, and looks forward to the potential application prospects of METTL3 inhibitors in clinical practice.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Design Example: Application of Archimedes' Principle
The volume of seawater displaced by the block is determined by first calculating the block's weight. This is done by multiplying the...
Group Design
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Factorial Design
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...


